Top Markets
#1 Seeker Seeker +15.40%
#2 Official Trump Official Trump +12.94%
#3 DeFi Kingdoms DeFi Kingdoms +10.56%
#4 Ethena Staked ENA Ethena Staked ENA +9.25%
#5 EXOD EXOD +9.04%
#6 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +8.10%
#7 peaq peaq +7.28%
#8 TDCCP TDCCP +5.86%
#9 Melania Meme Melania Meme +5.55%
#10 Stacks Stacks +5.26%
Coin of the day
Seeker Seeker
Settings
Language
ENGLISH
Currency
USD
Theme
Nanjing Leads Biolabs Co Ltd Nanjing Leads Biolabs Co Ltd

Nanjing Leads Biolabs Co Ltd

9887
Rank in Stocks #6838
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the... Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
Share Price
$9.22
Last synced: 2026-08-27
Market Cap
$1.83B
Change (1 day)
0.91%
Change (1 year)
20.95%
Country
CN
Trade Nanjing Leads Biolabs Co Ltd (9887)

Category

Healthcare
P/E ratio for Nanjing Leads Biolabs Co Ltd (9887)
P/E ratio as of 2026 TTM: 0
According to Nanjing Leads Biolabs Co Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nanjing Leads Biolabs Co Ltd from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.